Flixonase Safety in Patients With Allergic Rhinitis (AR)

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Rhinitis, Allergic, Perennial
Interventions
DRUG

Intermittent, sub-chronic and chronic Flixonase use

Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.

DRUG

Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase

Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY